Oral Antibacterials Inc. launches UNO Gel for dentin hypersensitivity in collaboration with Germiphene Corporation


TORONTO, ON--(Marketwired - October 28, 2016) - Oral Antibacterials Inc., in collaboration with Germiphene Corporation, recently launched UNO Gel to dentists and dental hygienists across Canada. UNO Gel provides rapid and long-lasting relief from dentin hypersensitivity, a common dental complaint that can significantly impair eating, drinking or speaking.

The innovation behind UNO Gel is the result of extensive research by Oral Antibacterials co-founder Dr. Anil Kishen and his lab at the University of Toronto. "The bioactive polymer used in UNO forms a rapid, protective, dentin integrated layer to prevent hypersensitivity", said Dr. Kishen. The company has been working with the Impact Centre at the University of Toronto, including participating in the Techno summer entrepreneurship workshop, to translate their science and expertise into innovative products.

The partnership with Germiphene Corporation, a leader in dental infection control and oral care products, will help accelerate the commercialization and distribution of this innovative product. "UNO is the most exciting product launched by Germiphene Corporation in a long time," said George Botos, VP of Business Development at Germiphene. "We really believe that the technology commercialized by Oral Antibacterials will create a new industry standard in terms of hypersensitivity treatment in the dental office."

About Oral Antibacterials Inc.
Oral Antibacterials Inc. was founded by University of Toronto scientists in the Faculty of Dentistry. Experts in the fields of biomaterials, nanotechnology and optics, they are dedicated to bringing the latest scientific advances into practice.

About Germiphene Corporation
Germiphene Corporation has been a leader in dental infection control and oral care products for over 60 years. Founded in 1952, their expertise in manufacturing, microbiology and chemistry has resulted in the launch of innovative products and the improvement the oral health around the world.

About the Impact Centre
The Impact Centre is a research institute at the University of Toronto that strives to bring science to society through industry projects and partnerships, entrepreneurial companies, and unique training programs. We connect exceptional research, talent, innovative companies, and government to create products and services both for existing industry partners and as the basis for startups.

Image Available: http://www.marketwire.com/library/MwGo/2016/10/27/11G119844/Images/Kishen-Shrestha_Lab_Portrait_2016-10-20_004_(1)-d3bf8cd0b341a95d8061b75422f585f5.jpg

Contact Information:

Contact Information:
Scott McAuley
Communications Coordinator
Impact Centre
smcauley@imc.utoronto.ca

Oral Antibiotics Inc. co-founders Dr. Annie Shrestha and Prof. Anil Kishen in their lab at the University of Toronto.